SG11201901317TA - Anti-pd-l1 antibody - Google Patents
Anti-pd-l1 antibodyInfo
- Publication number
- SG11201901317TA SG11201901317TA SG11201901317TA SG11201901317TA SG11201901317TA SG 11201901317T A SG11201901317T A SG 11201901317TA SG 11201901317T A SG11201901317T A SG 11201901317TA SG 11201901317T A SG11201901317T A SG 11201901317TA SG 11201901317T A SG11201901317T A SG 11201901317TA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- amino acid
- acid sequence
- seq
- rat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016159089 | 2016-08-15 | ||
| JP2016159088 | 2016-08-15 | ||
| JP2017061454 | 2017-03-27 | ||
| JP2017110723 | 2017-06-05 | ||
| PCT/JP2017/029055 WO2018034225A1 (fr) | 2016-08-15 | 2017-08-10 | Anticorps anti-pd-l1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901317TA true SG11201901317TA (en) | 2019-03-28 |
Family
ID=61196830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901317TA SG11201901317TA (en) | 2016-08-15 | 2017-08-10 | Anti-pd-l1 antibody |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11312773B2 (fr) |
| EP (1) | EP3498838A4 (fr) |
| JP (1) | JP6960634B2 (fr) |
| KR (2) | KR102569068B1 (fr) |
| CN (1) | CN109790533B (fr) |
| AU (1) | AU2017313494B2 (fr) |
| BR (1) | BR112019002852A2 (fr) |
| CA (1) | CA3033896A1 (fr) |
| MX (1) | MX2019001896A (fr) |
| PH (1) | PH12019500319A1 (fr) |
| RU (1) | RU2744862C2 (fr) |
| SG (1) | SG11201901317TA (fr) |
| WO (1) | WO2018034225A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201901317TA (en) * | 2016-08-15 | 2019-03-28 | Univ Hokkaido Nat Univ Corp | Anti-pd-l1 antibody |
| CN110869055B (zh) | 2017-07-20 | 2023-04-28 | 国立大学法人北海道大学 | 靶向pd-1/pd-l1的抑制剂与cox-2抑制剂的组合使用 |
| CN111018989B (zh) * | 2019-12-16 | 2021-03-23 | 郑州大学 | 一种抗pd-l1单克隆抗体以及在制备抗癌药物方面的应用 |
| WO2024085686A1 (fr) * | 2022-10-19 | 2024-04-25 | 충남대학교 산학협력단 | Protéine recombinante comprenant une protéine dérivée de la protéine de capside du virus de la fièvre aphteuse et de la protéine sfc et son utilisation |
| WO2024160721A1 (fr) | 2023-01-30 | 2024-08-08 | Kymab Limited | Anticorps |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP2811102B2 (ja) | 1989-12-28 | 1998-10-15 | 財団法人化学及血清療法研究所 | ネコ免疫グロブリンγ鎖の定常領域をコードする遺伝子断片およびマウス×ネコキメラ抗体 |
| JP2837240B2 (ja) | 1990-06-07 | 1998-12-14 | 財団法人化学及血清療法研究所 | イヌ免疫グロブリンγ鎖の定常領域をコードする遺伝子断片およびマウス×イヌキメラ抗体 |
| AU640397B2 (en) * | 1989-08-25 | 1993-08-26 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin |
| DK1907424T3 (en) * | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
| HUE049647T2 (hu) * | 2009-11-24 | 2020-09-28 | Medimmune Ltd | Targetált kötõdõ ágensek B7-H1 ellen |
| US20150011431A1 (en) | 2012-01-09 | 2015-01-08 | The Scripps Research Institute | Humanized antibodies |
| AU2013271564A1 (en) | 2012-06-06 | 2014-12-04 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
| CN105073781A (zh) | 2013-01-11 | 2015-11-18 | 加州生物医学研究所 | 牛融合抗体 |
| WO2015035173A1 (fr) * | 2013-09-05 | 2015-03-12 | Duke University | Anticorps nav1.7 et leurs méthodes d'utilisation |
| RU2535629C1 (ru) | 2013-11-12 | 2014-12-20 | Дмитрий Андреевич Соколов | Элемент конструктора (варианты) и конструктор |
| WO2015091911A2 (fr) * | 2013-12-20 | 2015-06-25 | Intervet International B.V. | Anticorps dirigés contre la pd-1 canine |
| CA2961987A1 (fr) * | 2014-09-30 | 2016-04-07 | Intervet International B.V. | Anticorps pd-l1 de liaison a pd-l1 canin |
| BR112018006953A2 (pt) * | 2015-10-05 | 2018-10-23 | Circle33 Llc | anticorpos com estabilidade melhorada para digestão intestinal |
| SG11201901317TA (en) * | 2016-08-15 | 2019-03-28 | Univ Hokkaido Nat Univ Corp | Anti-pd-l1 antibody |
-
2017
- 2017-08-10 SG SG11201901317TA patent/SG11201901317TA/en unknown
- 2017-08-10 KR KR1020197007407A patent/KR102569068B1/ko active IP Right Grant
- 2017-08-10 KR KR1020237027172A patent/KR20230125085A/ko not_active Application Discontinuation
- 2017-08-10 US US16/325,040 patent/US11312773B2/en active Active
- 2017-08-10 JP JP2018534377A patent/JP6960634B2/ja active Active
- 2017-08-10 BR BR112019002852A patent/BR112019002852A2/pt unknown
- 2017-08-10 WO PCT/JP2017/029055 patent/WO2018034225A1/fr unknown
- 2017-08-10 CA CA3033896A patent/CA3033896A1/fr active Pending
- 2017-08-10 RU RU2019105697A patent/RU2744862C2/ru active
- 2017-08-10 EP EP17841448.8A patent/EP3498838A4/fr active Pending
- 2017-08-10 MX MX2019001896A patent/MX2019001896A/es unknown
- 2017-08-10 CN CN201780050320.XA patent/CN109790533B/zh active Active
- 2017-08-10 AU AU2017313494A patent/AU2017313494B2/en active Active
-
2019
- 2019-02-14 PH PH12019500319A patent/PH12019500319A1/en unknown
-
2022
- 2022-01-19 US US17/579,517 patent/US20220227871A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019105697A3 (fr) | 2020-09-17 |
| AU2017313494A1 (en) | 2019-03-07 |
| MX2019001896A (es) | 2019-08-29 |
| AU2017313494B2 (en) | 2023-09-21 |
| CN109790533B (zh) | 2023-04-04 |
| CA3033896A1 (fr) | 2018-02-22 |
| KR20230125085A (ko) | 2023-08-28 |
| EP3498838A1 (fr) | 2019-06-19 |
| WO2018034225A1 (fr) | 2018-02-22 |
| EP3498838A4 (fr) | 2020-01-08 |
| KR102569068B1 (ko) | 2023-08-21 |
| JP6960634B2 (ja) | 2021-11-05 |
| KR20190039256A (ko) | 2019-04-10 |
| US11312773B2 (en) | 2022-04-26 |
| BR112019002852A2 (pt) | 2019-06-25 |
| US20210277124A1 (en) | 2021-09-09 |
| US20220227871A1 (en) | 2022-07-21 |
| RU2744862C2 (ru) | 2021-03-16 |
| CN109790533A (zh) | 2019-05-21 |
| JPWO2018034225A1 (ja) | 2019-06-20 |
| PH12019500319A1 (en) | 2019-10-21 |
| RU2019105697A (ru) | 2020-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019001897A (es) | Anticuerpo anti-lag-3. | |
| SG11201901317TA (en) | Anti-pd-l1 antibody | |
| CO2019007844A2 (es) | Anticuerpo anti-receptor de transferrina humana novedoso capaz de penetrar la barrera hematoencefálica | |
| MX2020009275A (es) | Composiciones de anticuerpo anti-pd-1. | |
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| NZ719036A (en) | Anti-pdl1 antibody formulations | |
| AR110321A1 (es) | Anticuerpos antitau y métodos de uso | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| PE20130393A1 (es) | Anticuerpos con union de antigenos dependiente de ph | |
| MX2019007347A (es) | Anticuerpo anti-cd3 y moleculas que comprenden el anticuerpo. | |
| MX2020008736A (es) | Formulaciones de anticuerpos b7-h4. | |
| MX2019001841A (es) | Anticuerpo anti-pd-1. | |
| MX2020007406A (es) | Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. | |
| EA202092336A1 (ru) | Соединения, обладающие пестицидным действием, композиции и способ борьбы с вредителями, связанные с ними | |
| MX2021005085A (es) | Formulacion de anticuerpo. | |
| PH12019502023A1 (en) | Anti-pd-l1 antibody for detecting pd-l1 | |
| MX2020005555A (es) | Construcciones inmunogenicas de peptidos de tau. | |
| MY195550A (en) | Antibody Formulation | |
| AR102593A1 (es) | Anticuerpos anti-pdgf-b y métodos de uso | |
| EA202092508A1 (ru) | Составы на основе антител к pd-l1 человека | |
| MX2021009851A (es) | Formulacion de anticuerpos terapeuticos. | |
| MX2022013566A (es) | Anticuerpo. | |
| CR20220322A (es) | Formulaciones de anticuerpos anti-pd-l1 | |
| MX2021007047A (es) | Formulaciones de anticuerpos. | |
| MX2017013480A (es) | Composicion farmaceutica para tratar y/o prevenir el cancer. |